Biogen Continues To Plot New Course In Naming Two Key Executives. But Is Independence Part Of The Plan?
This article was originally published in The Pink Sheet Daily
Executive Summary
The big biotech announces Steve Holtzman, former chairman of Infinity, as head of corporate development, with Doug Williams, former CEO of ZymoGenetics stepping in as exec VP of R&D.
You may also be interested in...
Biogen/Elan Submit Applications For Tysabri Label Change Ahead of Schedule
In a bid to solidify Tysabri's place in an increasingly competitive market, Biogen/Elan push forward with changes to the multiple sclerosis medicine's label that help define the risk of a rare brain infection.
Gilenya Could Surpass Avonex Market Share, Analysts Say
Novartis' Gilenya is fresh out of the gate, but stands to collect a large share of the MS market, Leerink Swann analysts predict in a report.